Springtime For RINOs Authored by James Howard Kunstler, “This sort of derangment is a novel psychopathology in the human species. . . a synthesis of low-IQ feminized brain scramble & neurotic lunacy ." - JD Haltigan on X Went to the No Kings assemblies in my town and the next nearby town on Saturday. Mental illness as far as the eye could see. Old folks, too, as far as the eye could see, predomina...
Springtime For RINOs Authored by James Howard Kunstler, “This sort of derangment is a novel psychopathology in the human species. . . a synthesis of low-IQ feminized brain scramble & neurotic lunacy ." - JD Haltigan on X Went to the No Kings assemblies in my town and the next nearby town on Saturday. Mental illness as far as the eye could see. Old folks, too, as far as the eye could see, predominately of the female persuasion: the devouring grandmothers . The Democratic Party has marshalled mental illness as its premier campaign strategy, and lately it is winning bigly around the country as mental illness becomes the go-to cope option for the ragged remnants of Boomerdom. They believe things that are patently insane, for instance, the latest proposal by Rep. Pramila Jayapal (D-WA) that illegal immigrants deserve reparations on account of being “traumatized” by U.S. immigration enforcement actions. If it feels like the Democratic Party is at war with our country you are not hallucinating. It is every bit as much a jihad as the Death to America crowd in Iran has explicitly pushed since 1979. The president gets no help whatsoever from his own party, as you see in the disgraceful hijinks around the urgent issue of election reform. You know exactly how the election playbook was written: let x-million foreigners into the country illegally, give them (illegally) social security numbers, driver’s licenses, automatic voter registrations, addresses, mail-in ballots. . . and voila! They don’t even have to mail-in their own mail-in ballots. Lawfare ninja Marc Elias will arrange ballot pick-up service. And the cherry on top is that the census must count all the illegal aliens to add new congressional districts for extra seats in Congress. So, in the face of that, Republican Majority Leader John Thune could not muster enough votes to save the SAVE Act. Or so he said. Looks more like lack a’wanna. Eerie lack a’wanna. On their tours of cable news, the hapless Republican senators, w...
The clock is ticking on Nike's recovery. Without any signs of improvement, Jim Cramer said we may soon have to make a hard decision on the stock. "I want to wait until the fall before we cashier [Nike's stock] and take the loss, or I see some green shoots by then," Jim said Friday during the March Monthly Meeting . "If I see some green shoots, we could buy some more." Jim's commentary comes ahead ...
The clock is ticking on Nike's recovery. Without any signs of improvement, Jim Cramer said we may soon have to make a hard decision on the stock. "I want to wait until the fall before we cashier [Nike's stock] and take the loss, or I see some green shoots by then," Jim said Friday during the March Monthly Meeting . "If I see some green shoots, we could buy some more." Jim's commentary comes ahead of Nike's critical fiscal 2026 third-quarter earnings report Tuesday night. It is CEO Elliott Hill's latest chance to show a skeptical Wall Street that his "Win Now" turnaround initiative is working. Since taking over in October 2024, Hill has made changes to executive leadership, managed to largely clear a backlog of classics inventory, and introduced a fresh lineup of products. Some of its recent drops include the Nike Mind collection , which officially launched in January, and the NikeSKIMS activewear collaboration with Kim Kardashian's brand. New, exciting collections can help drive sales and reinvigorate the brand. But so far, nothing has been enough to sustain momentum in the stock — not even the Supreme Court striking down President Donald Trump's emergency tariffs last month, on its face a win for companies like Nike that have seen their profits squeezed by elevated import duties. Nike shares are down more than 18% year to date, with the vast majority of the declines coming since the Iran war broke out on Feb. 28 and muddied the outlook for the global economy. At roughly $51 per share on Monday, the stock is down roughly 35% from its 52-week closing high of $79.24 in July. Nike's performance in China will be under the microscope Tuesday night, just as it was when the company reported second-quarter results in mid-December. In the three months ended in November, Nike's Greater China segment saw a 17% year-over-year decline in sales, and executives guided for similar performance in the third quarter. That was one of the biggest reasons the stock plummeted 10.5% the fo...
Nikada Wall Street’s major indexes closed lower on Monday as investors navigated the start of a holiday-shortened week, with attention still firmly fixed on developments in the Middle East. The tech-heavy Nasdaq Composite ( COMP:IND ) led the declines, falling 1.2%, while the S&P 500 ( SP500 ) slipped 0.7%. The Dow Jones Industrial Average ( DJI ) was more resilient, edging down 0.2%. Now, here ar...
Nikada Wall Street’s major indexes closed lower on Monday as investors navigated the start of a holiday-shortened week, with attention still firmly fixed on developments in the Middle East. The tech-heavy Nasdaq Composite ( COMP:IND ) led the declines, falling 1.2%, while the S&P 500 ( SP500 ) slipped 0.7%. The Dow Jones Industrial Average ( DJI ) was more resilient, edging down 0.2%. Now, here are three focus points for investors on Tuesday: Traders will be closely watching Tuesday’s release of the JOLTS report after the open, as investors seek fresh insight into labor market demand and overall economic resilience. The data will be closely analyzed for changes in job openings, hiring trends, and quits rates, all of which could influence expectations for wage pressures and help shape the Federal Reserve’s policy outlook. Market participants will also focus on the Chicago PMI release, looking for updated signals on regional manufacturing activity and broader business conditions. The data will be parsed for trends in demand, output, and input costs, which may offer clues on economic strength and inform expectations around the Federal Reserve’s next moves. Investors are expected to keep a close eye on crude oil ( CL1:COM ) as tensions between the U.S. and Iran continue to inject volatility into energy markets and broader investor sentiment. With prices settling above $104 per barrel on Monday, traders will be alert to further fluctuations driven by geopolitical headlines and any threats to supply flows, particularly through critical chokepoints such as the Strait of Hormuz. Market Tracking ETFs: ( DIA ), ( DDM ), ( DOG ), ( DXD ), ( SDOW ), ( SPY ), ( VOO ), ( IVV ), ( RSP ), ( SSO ), ( UPRO ), ( SH ), ( SDS ), ( SPXU ), ( QQQ ), ( QQQM ), ( TQQQ ), ( QID ), and ( SQQQ ). More on markets S&P 500 is on pace for its worst month since 2022 as broad selloff deepens Selling pressure intensifies as now nearly 300 of the S&P 500 names trade lower in 2026 Recession odds in 202...
AI adoption is rising in the U.S., but trust remains low, with most Americans concerned about transparency, regulation, and the technology’s broader societal impact, according to a new Quinnipiac poll.
AI adoption is rising in the U.S., but trust remains low, with most Americans concerned about transparency, regulation, and the technology’s broader societal impact, according to a new Quinnipiac poll.
Defiance ETFs CEO and CIO Sylvia Jablonski and Yahoo Finance Tech Editor chat about this year's hottest anticipated initial public offerings (IPOs): OpenAI (OPAI.PVT), Anthropic (ANTH.PVT), and SpaceX (SPAX.PVT).
Defiance ETFs CEO and CIO Sylvia Jablonski and Yahoo Finance Tech Editor chat about this year's hottest anticipated initial public offerings (IPOs): OpenAI (OPAI.PVT), Anthropic (ANTH.PVT), and SpaceX (SPAX.PVT).
CIBC Private Wealth Senior Energy Trader Rebecca Babin discusses US oil settling above $100 per barrel for the first time since the start of the Iran War, and why the oil situation is moving from a 'chokehold' to a 'stranglehold.' She talks with Katie Greifeld and Bailey Lipschultz on "The Close." (Source: Bloomberg)
CIBC Private Wealth Senior Energy Trader Rebecca Babin discusses US oil settling above $100 per barrel for the first time since the start of the Iran War, and why the oil situation is moving from a 'chokehold' to a 'stranglehold.' She talks with Katie Greifeld and Bailey Lipschultz on "The Close." (Source: Bloomberg)
The suit is centered around the alleged attempt on Anssaf Ali Mayo's life. But it raises broader questions, including about the role of the United Arab Emirates in Yemen's civil war. (Image credit: Mohammed Huwais)
The suit is centered around the alleged attempt on Anssaf Ali Mayo's life. But it raises broader questions, including about the role of the United Arab Emirates in Yemen's civil war. (Image credit: Mohammed Huwais)
Mohamad Faizal Bin Ramli/iStock via Getty Images Just over one month ago , I upgraded Corcept Therapeutics Incorporated ( CORT ) to Buy following the company's loss in its patent litigation against Teva Pharmaceuticals ( TEVA ). This was a setback for the company, allowing Teva to release a generic version of Corcept's drug Korlym and potentially calling into question the legacy Cushing's syndrome...
Mohamad Faizal Bin Ramli/iStock via Getty Images Just over one month ago , I upgraded Corcept Therapeutics Incorporated ( CORT ) to Buy following the company's loss in its patent litigation against Teva Pharmaceuticals ( TEVA ). This was a setback for the company, allowing Teva to release a generic version of Corcept's drug Korlym and potentially calling into question the legacy Cushing's syndrome franchise that delivered $761M in 2025 sales. Counterintuitively, this development marked a bottom for the stock, pricing in the bad news, while upside from Corcept's new drug Lifyorli (relacorilant) provided a catalyst to move higher. Indeed, the stock had been punished severely in 2025 due to the patent litigation loss and the FDA deciding not to move forward with an approval of relacorilant for Cushing's syndrome. The latter would have enabled Corcept to protect its Korlym sales by switching patients to the newer drug. However, the stock market is forward-looking, and uncertainty has now started to clear. Analyzing Corcept's balance sheet , I became bullish because the company had ample liquidity to pivot to ovarian cancer, reinventing itself into a growing oncology franchise. On Wednesday, the FDA issued a decision that came earlier than anticipated, granting approval for relacorilant in platinum-resistant ovarian cancer (the PDUFA date had been mid-July). This development is bullish for Corcept because the regulatory risk surrounding approval of relacorilant is gone. Now the question is execution: can the company grow sales of its newly approved drug quickly enough to offset generic competition of Korlym? Due to the quality of data, the breadth of the approval, and the first-in-class mechanism of a selective glucocorticoid receptor antagonist (SGRA) for oncology, I believe that the odds are now in Corcept's favor. While the stock has rallied from $33 to $38 since my last article, there is ample upside ahead if Corcept can successfully commercialize its new drug. As su...
M&T Bank ( MTB ) on Monday said its board has authorized a share repurchase program of up to $5 billion of its common stock. The new authorization replaces and terminates a previous $4 billion buyback program approved in January 2025. The company said the timing, number of shares repurchased, and transaction terms will be at its discretion and subject to regulatory limits. Source: Press Release Mo...
M&T Bank ( MTB ) on Monday said its board has authorized a share repurchase program of up to $5 billion of its common stock. The new authorization replaces and terminates a previous $4 billion buyback program approved in January 2025. The company said the timing, number of shares repurchased, and transaction terms will be at its discretion and subject to regulatory limits. Source: Press Release More on M&T Bank M&T Bank: A Defensive Holding In An Uncertain Market M&T Bank Corporation (MTB) Presents at RBC Capital Markets Global Financial Institutions Conference 2026 Transcript M&T Bank Corporation (MTB) Q4 2025 Earnings Call Transcript M&T Bank outlines 2026 NII target of $7.2B–$7.35B with broad-based loan growth focus M&T Bank Q4 earnings beat as noninterest income exceeds consensus